Product Description
AZD5213 is potent, competitive, rapidly reversible, functional antagonist (inverse agonist) at the human H3 receptor. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd5213.html)
Mechanisms of Action: H3 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease|Cognitive Dysfunction|Tourette Syndrome|Rett Syndrome|Low Back Pain
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D3031C00001 | P2 |
Completed |
Low Back Pain |
2015-05-01 |
|
| D3032C00001 | P2 |
Completed |
Rett Syndrome|Tourette Syndrome |
2015-02-01 |
|
| D3030C00005 | P2 |
Completed |
Alzheimer Disease|Cognitive Dysfunction |
2013-01-01 |
|
| D3030C00004 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |